NRXS Key Statistics, Chart & Performance
The current stock price of NRXS is 4.91 USD. In the past month the price increased by 52.48%. In the past year, price increased by 57.39%.
NRXS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to NRXS. When comparing the yearly performance of all stocks, NRXS is one of the better performing stocks in the market, outperforming 92.72% of all stocks.
NRXS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NRXS. NRXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NRXS Financial Highlights
Over the last trailing twelve months NRXS reported a non-GAAP Earnings per Share(EPS) of -1.01. The EPS increased by 66.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -110.11% | ||
| ROE | -183.49% | ||
| Debt/Equity | 0 |
NRXS Forecast & Estimates
8 analysts have analysed NRXS and the average price target is 6.5 USD. This implies a price increase of 32.43% is expected in the next year compared to the current price of 4.91.
For the next year, analysts expect an EPS growth of -890% and a revenue growth -70.39% for NRXS
NRXS Ownership
NRXS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.19 | 209.93B | ||
| ISRG | INTUITIVE SURGICAL INC | 60.82 | 185.65B | ||
| SYK | STRYKER CORP | 27.56 | 138.80B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.09 | 135.95B | ||
| BDX | BECTON DICKINSON AND CO | 14.3 | 58.85B | ||
| IDXX | IDEXX LABORATORIES INC | 55.23 | 55.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.13 | 49.41B | ||
| RMD | RESMED INC | 26.19 | 37.85B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.67 | 36.94B | ||
| DXCM | DEXCOM INC | 38.77 | 28.12B | ||
| PODD | INSULET CORP | 62.35 | 20.05B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.7 | 17.15B |
Related stock screener links
About NRXS
Company Profile
NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. The company is headquartered in Carmel, Indiana and currently employs 21 full-time employees. The company went IPO on 2023-08-09. The firm is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. The company focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Company Info
NEURAXIS INC
11611 N. Meridian St, Suite 330
Carmel INDIANA US
Employees: 21
Phone: 18126890791
NEURAXIS INC / NRXS FAQ
What does NRXS do?
NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. The company is headquartered in Carmel, Indiana and currently employs 21 full-time employees. The company went IPO on 2023-08-09. The firm is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. The company focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Can you provide the latest stock price for NEURAXIS INC?
The current stock price of NRXS is 4.91 USD. The price increased by 5.59% in the last trading session.
Does NRXS stock pay dividends?
NRXS does not pay a dividend.
What is the ChartMill rating of NEURAXIS INC stock?
NRXS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy NRXS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NRXS.
Can you provide the upcoming earnings date for NEURAXIS INC?
NEURAXIS INC (NRXS) will report earnings on 2026-03-20.
What is the Short Interest ratio of NEURAXIS INC (NRXS) stock?
The outstanding short interest for NEURAXIS INC (NRXS) is 4.61% of its float.